Clinical Trials

Inclusion Criteria:

- The participant must provide study-specific informed consent prior to any study
specific procedures and authorization permitting release of personal health
information.

- The participant must have a first time diagnosis of non-metastatic breast cancer which
is Stage I-III.

- The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive
Function 4a.

- Participants with greater than or equal to 6 months to 5 years post-treatment
(completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) except may
still be taking endocrine therapy or HER2-directed adjuvant therapy.

- The participant must be able to understand, speak, read, and write in English or
Spanish.

Exclusion Criteria:

- Scoring less than or equal to 3 on the 6-item cognitive screen.

- Patient Health Questionnaire-2 item (PHQ-2) score of greater than or equal to 3.

- Definitive clinical or radiologic evidence of metastatic disease.

- Prior history of past or current other cancer, except for non-melanoma skin cancer or
in situ cervical cancer within the past 5 years.

- Previous exposure to chemotherapy treatment for another cancer or due to other medical
condition (e.g. methotrexate exposure for treatment of rheumatoid arthritis).

- Previous central nervous system (CNS) radiation, intrathecal therapy or CNS-involved
surgery.

- Participants with history of stroke, traumatic brain injury, brain surgery,
Alzheimer's disease or other dementia.

- Participants with active substance abuse and/or in treatment for substance abuse, or
history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/7/2024. Questions regarding updates should be directed to the study team contact.